An Outtier

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

Bram Verstockt, Erwin Dreesen, Maja Noman et al. · Journal of Crohn s and Colitis · 2019 · 121 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study

Laurent Goessens, Jean‐Frédéric Colombel, An Outtier et al. · United European Gastroenterology Journal · 2021 · 71 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients

Bram Verstockt, Evelien Mertens, Erwin Dreesen et al. · Journal of Crohn s and Colitis · 2019 · 38 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn’s Disease in a Randomized Placebo-Controlled Trial

Jessica R. de Bruyn, Peter Bossuyt, Marc Ferrante et al. · Clinical Gastroenterology and Hepatology · 2020 · 37 citations · Full text

Medicine, Immunology, Nutrition +17

Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases

Wannee Kantasiripitak, An Outtier, Sebastian G. Wicha et al. · CPT Pharmacometrics & Systems Pharmacology · 2022 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17